Posters

Presbyond LBV based on micromonovision for the correction of presbyopia – preliminary results

Poster Details

First Author: K.Skonieczna POLAND

Co Author(s):    B. Czarnota-Nowakowska   D. Janiszewska-Bil                 

Abstract Details

Purpose:

To evaluate the safety and efficacy of Presbyond Laser Blended Vision (LBV) for the correction of myopia with presbyopia and hyperopia with presbyopia.

Setting:

Optegra Eye Clinic in Warsaw (Poland) Optegra Eye Clinic in Poznan (Poland) Optegra Eye Clinic in Katowice (Poland)

Methods:

This retrospective analysis included 82 eyes of 41 patients with myopia and presbyopia and 46 eyes of 23 patients with hyperopia and presbyopia treated by Presbyond LBV using the non-linear aspheric ablation profile with the MEL 90 (Carl Zeiss Meditec, Jena, Germany) and femtosecond laser VisuMax to create the flap. The target refraction was plano for distance eyes (dominant eye) and between -0.75 and -2.0 diopters (D) for near eyes. Patients were followed for 3 months after surgery.

Results:

Mean corrected myopia was -3,60D (range: -1,00D to -8,00D) hyperopia was +1,80D (range: +1,00D to +2,25D) and mean cylinder was 0,70D (range: 0,00D to 2,50D). Mean age was 49,5 years (range: 40 do 64 years). Postoperative spherical equivalent in dominant eye was ±0,50D in 95% of myopic eyes and in 87% of hyperopic eyes. Of the distance eyes, 85% of myopic eyes and 74% of hyperopic eyes achieved uncorrected visual acuity of 20/20 and 100% of myopic and hyperopic eyes achieved 20/40. Binocularly, 97% of patients with myopia and 87% of patients with hyperopia achieved 20/20 and 100% achieved 20/32. Binocularly, 100% patients with myopia and 96% of patients with hyperopia could read J2 and 100% could read J5. No eyes lost two or more lines in best spectacle-corrected visual acuity.

Conclusions:

Presbyond LBV with the MEL 90 excimer laser is safe and effective for treating myopia with presbyopia and hyperopia with presbyopia.

Financial Disclosure:

travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented